Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematology | 2 | 2023 | 221 | 0.890 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2024 | 236 | 0.860 |
Why?
|
Referral and Consultation | 4 | 2024 | 3528 | 0.830 |
Why?
|
Factor Xa | 1 | 2021 | 162 | 0.730 |
Why?
|
Vitamin B 12 Deficiency | 1 | 2020 | 116 | 0.700 |
Why?
|
Thrombotic Microangiopathies | 1 | 2020 | 132 | 0.660 |
Why?
|
Neutropenia | 1 | 2024 | 895 | 0.660 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2022 | 365 | 0.650 |
Why?
|
Blood Sedimentation | 1 | 2019 | 231 | 0.640 |
Why?
|
Purpura | 1 | 2018 | 122 | 0.610 |
Why?
|
Internal Medicine | 1 | 2024 | 1009 | 0.570 |
Why?
|
Eosinophilia | 1 | 2020 | 541 | 0.550 |
Why?
|
Internship and Residency | 6 | 2022 | 5788 | 0.540 |
Why?
|
Giant Cell Arteritis | 1 | 2019 | 292 | 0.510 |
Why?
|
Urate Oxidase | 1 | 2014 | 35 | 0.480 |
Why?
|
Methemoglobinemia | 1 | 2014 | 44 | 0.480 |
Why?
|
Inpatients | 3 | 2022 | 2518 | 0.460 |
Why?
|
Gout Suppressants | 1 | 2014 | 166 | 0.430 |
Why?
|
Clinical Competence | 5 | 2023 | 4687 | 0.420 |
Why?
|
Recombinant Proteins | 1 | 2021 | 6622 | 0.390 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2019 | 1052 | 0.350 |
Why?
|
Venous Thrombosis | 1 | 2018 | 1239 | 0.340 |
Why?
|
Medical Oncology | 2 | 2022 | 2265 | 0.330 |
Why?
|
Teaching Rounds | 3 | 2022 | 253 | 0.330 |
Why?
|
Hospitals | 1 | 2021 | 3952 | 0.300 |
Why?
|
Education, Medical, Graduate | 5 | 2023 | 2291 | 0.290 |
Why?
|
Hospitalists | 2 | 2021 | 305 | 0.280 |
Why?
|
Curriculum | 6 | 2022 | 3605 | 0.240 |
Why?
|
Burnout, Professional | 3 | 2020 | 694 | 0.220 |
Why?
|
Pandemics | 2 | 2022 | 8388 | 0.220 |
Why?
|
Stroke | 1 | 2024 | 9981 | 0.200 |
Why?
|
Vermont | 1 | 2020 | 85 | 0.190 |
Why?
|
Accreditation | 1 | 2023 | 450 | 0.180 |
Why?
|
North America | 1 | 2023 | 1249 | 0.180 |
Why?
|
Problem Solving | 1 | 2022 | 440 | 0.170 |
Why?
|
Humans | 35 | 2024 | 744343 | 0.170 |
Why?
|
Focus Groups | 1 | 2024 | 1321 | 0.170 |
Why?
|
Venous Thromboembolism | 2 | 2022 | 1671 | 0.170 |
Why?
|
Family Conflict | 1 | 2019 | 95 | 0.170 |
Why?
|
Lymphocyte Count | 1 | 2020 | 793 | 0.160 |
Why?
|
Translocation, Genetic | 1 | 2024 | 1420 | 0.160 |
Why?
|
Kinesics | 1 | 2017 | 13 | 0.150 |
Why?
|
Physicians | 3 | 2020 | 4567 | 0.150 |
Why?
|
Communication | 3 | 2022 | 3749 | 0.150 |
Why?
|
Blood Coagulation Disorders | 1 | 2020 | 337 | 0.150 |
Why?
|
Nonverbal Communication | 1 | 2017 | 63 | 0.150 |
Why?
|
Psychological Theory | 1 | 2018 | 168 | 0.150 |
Why?
|
Rheumatology | 1 | 2022 | 576 | 0.140 |
Why?
|
Teaching | 3 | 2021 | 1174 | 0.140 |
Why?
|
Trauma Centers | 1 | 2021 | 890 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2015 | 578 | 0.120 |
Why?
|
Diagnosis, Differential | 2 | 2020 | 12959 | 0.120 |
Why?
|
Immunoglobulin M | 1 | 2019 | 1537 | 0.120 |
Why?
|
Self Efficacy | 1 | 2018 | 616 | 0.120 |
Why?
|
Adenocarcinoma | 3 | 2016 | 6364 | 0.120 |
Why?
|
Bone Marrow | 1 | 2024 | 2948 | 0.120 |
Why?
|
Personal Satisfaction | 1 | 2018 | 643 | 0.110 |
Why?
|
Patient Care | 1 | 2019 | 640 | 0.110 |
Why?
|
Mutagenesis, Insertional | 1 | 2016 | 655 | 0.110 |
Why?
|
Heparin | 1 | 2020 | 1637 | 0.110 |
Why?
|
Intelligence | 1 | 2018 | 920 | 0.110 |
Why?
|
Medicine | 1 | 2021 | 946 | 0.110 |
Why?
|
Vision Disorders | 1 | 2019 | 1058 | 0.100 |
Why?
|
Hypertension, Pulmonary | 1 | 2022 | 1537 | 0.100 |
Why?
|
Aged | 8 | 2020 | 163280 | 0.100 |
Why?
|
Learning | 2 | 2018 | 1713 | 0.100 |
Why?
|
Headache | 1 | 2019 | 1226 | 0.100 |
Why?
|
Gene Amplification | 1 | 2015 | 1063 | 0.100 |
Why?
|
Alternative Splicing | 1 | 2015 | 1117 | 0.090 |
Why?
|
Pulmonary Embolism | 1 | 2022 | 2376 | 0.090 |
Why?
|
Quinazolines | 1 | 2016 | 1356 | 0.090 |
Why?
|
Fatal Outcome | 1 | 2014 | 1850 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 2 | 2015 | 5535 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2019 | 1439 | 0.080 |
Why?
|
Motivation | 1 | 2018 | 1971 | 0.080 |
Why?
|
Boston | 1 | 2020 | 9313 | 0.080 |
Why?
|
C-Reactive Protein | 1 | 2019 | 3778 | 0.070 |
Why?
|
Biopsy | 1 | 2019 | 6756 | 0.070 |
Why?
|
Palliative Care | 1 | 2022 | 3493 | 0.070 |
Why?
|
Adult | 6 | 2022 | 214055 | 0.070 |
Why?
|
Lung Neoplasms | 3 | 2016 | 13102 | 0.070 |
Why?
|
Receptor, erbB-2 | 1 | 2016 | 2416 | 0.070 |
Why?
|
Education, Medical | 1 | 2018 | 1721 | 0.070 |
Why?
|
Retrospective Studies | 5 | 2020 | 77449 | 0.070 |
Why?
|
Students, Medical | 1 | 2018 | 1862 | 0.060 |
Why?
|
Pyrazoles | 1 | 2015 | 1972 | 0.060 |
Why?
|
Fellowships and Scholarships | 2 | 2022 | 1076 | 0.060 |
Why?
|
Pyridines | 1 | 2015 | 2825 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7279 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15076 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2019 | 5319 | 0.050 |
Why?
|
Faculty, Medical | 2 | 2021 | 1181 | 0.050 |
Why?
|
Male | 6 | 2022 | 350118 | 0.050 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 25043 | 0.040 |
Why?
|
Partial Thromboplastin Time | 1 | 2020 | 206 | 0.040 |
Why?
|
Female | 7 | 2022 | 380194 | 0.040 |
Why?
|
Jurisprudence | 1 | 2019 | 110 | 0.040 |
Why?
|
Problem-Based Learning | 1 | 2022 | 361 | 0.040 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2015 | 1660 | 0.040 |
Why?
|
Middle Aged | 2 | 2020 | 213383 | 0.040 |
Why?
|
United States | 2 | 2021 | 69872 | 0.030 |
Why?
|
Feedback | 1 | 2020 | 795 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2015 | 2455 | 0.030 |
Why?
|
Antineoplastic Agents | 2 | 2015 | 13695 | 0.030 |
Why?
|
Professional-Family Relations | 1 | 2019 | 482 | 0.030 |
Why?
|
Anticoagulants | 2 | 2020 | 4599 | 0.030 |
Why?
|
Peer Group | 1 | 2020 | 635 | 0.030 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2016 | 358 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2019 | 921 | 0.030 |
Why?
|
Interdisciplinary Communication | 1 | 2019 | 950 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 2 | 2015 | 4554 | 0.030 |
Why?
|
Adolescent | 1 | 2020 | 85781 | 0.030 |
Why?
|
Genomic Instability | 1 | 2015 | 695 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2015 | 63114 | 0.020 |
Why?
|
Mutation | 1 | 2015 | 29786 | 0.020 |
Why?
|
Leadership | 1 | 2020 | 1357 | 0.020 |
Why?
|
Hemorrhage | 1 | 2020 | 3461 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3743 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2016 | 6314 | 0.020 |
Why?
|
Prospective Studies | 2 | 2022 | 53288 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3229 | 0.020 |
Why?
|
Parents | 1 | 2019 | 3407 | 0.020 |
Why?
|
Cell Survival | 1 | 2015 | 5882 | 0.020 |
Why?
|
Risk Factors | 2 | 2022 | 72290 | 0.020 |
Why?
|
Phosphorylation | 1 | 2015 | 8436 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2727 | 0.010 |
Why?
|
Incidence | 1 | 2020 | 20947 | 0.010 |
Why?
|
Survival Rate | 1 | 2016 | 12788 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 19905 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2016 | 11031 | 0.010 |
Why?
|
Genotype | 1 | 2015 | 12951 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 16689 | 0.010 |
Why?
|
Genomics | 1 | 2015 | 5720 | 0.010 |
Why?
|
Cohort Studies | 1 | 2020 | 40561 | 0.010 |
Why?
|
Prognosis | 1 | 2016 | 29063 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2016 | 39050 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20129 | 0.010 |
Why?
|
Concepts
(137)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(52)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_